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5(6)-Epoxy-PGGr and 5(6)-epoxy-PGHr were isolated after incubation of microsomes of RSV with ‘H- 
labelled 5(6)-epoxy-C20:3 for 45 s at 37°C. The endoperoxides were methylated and characterized by 
conversion to prostaglandins. In buffer, the endoperoxides were converted to methyl-5(6)-epoxy-PGEr and 
methyl-5(6)-epoxy-15-hydroperoxy-PGEt, while treatment with SnClz reduced the endoperoxides to 
methyl-5-hydroxy-PGIr= and methyl-5-hydroxy-PGI v. Significant amounts of methyl-5(6)-epoxy-HHD 
were also formed. The endoperoxides could be separated by silicic acid chromatography and when 1 mM 
phenol was present in the incubation, 5(6)-epoxy-PGHi was obtained as the main product. 
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1. INTRODUCTION 
The isolation of the prostaglandin endoperox- 
ides PGGz and PGHz was reported in [l-3]. The 
prostaglandin endoperoxides were soon realized to 
be of considerable biological interest [4]. They are 
key intermediates in the biosynthesis of pro- 
staglandins, thromboxanes and prostacyclin and 
exert biological effects, which are different from 
many of their metabolites [l-4]. Consequently, 
many stable analogs of prostaglandin endoperox- 
ides have been developed [5]. 
5(6)-Epoxy-C20: 3 is one of the 4 epoxides 
formed from arachidonic acid by cytochrome 
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Abbreviations: PG, prostaglandin; RSV, ram seminal 
vesicles; Me&, trimethylsilyl; 5(6)-epoxy-C20: 3, 
cis-5(6)-epoxy-& 11,16eicosatrienoic acid; 5(6)-epoxy- 
HHD, cis-5(6)-epoxy-trans-8,l I-heptadecadienoic acid; 
GC-MS, gas chromatography-mass spectrometry; 
HPLC, high-performance liquid chromatography; UV, 
ultraviolet 
P-450 in the liver and renal cortex [6-81. This 
epoxide was recently found to be metabolized to 
prostaglandins by fatty acid cyclooxygenase [9]. 
The main products were identified as 5(6)-epoxy- 
PGEi, 5-hydroxy-PGIi, and 5-hydroxy-PGIV 
[9, lo], which all were assumed to be derived from 
the unstable 5(6)-epoxyprostaglandin endoperox- 
ides, 5(6)-epoxy-PGGi and 5(6)-epoxy-PGHi. The 
isolation of these endoperoxides as methyl esters is 
described here. 
2. MATERIALS AND METHODS 
2.1. Materials 
Arachidonic acid (99070) and sodium p- 
hydroxymercuribenzoate were purchased from 
Sigma. [3H]Arachidonic acid (100 Ci/mmol) and 
[‘4C]arachidonic acid (56 mCi/mmol) were ob- 
tained from the Radiochemical Centre, Amers- 
ham, England. Methoxyamine HCI and N,O- 
bis(trimethylsilyl)trifluoroacetamide were ob- 
tained from Pierce. Liquefied phenol was from 
Fisher. Silicic acid (Silicar CC-4) was from Mal- 
linckrodt. Other chemicals were from Merck. 
HPLC was performed as in [9,10]. Radioactivity 
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was determined with liquid scintillation 191. RSV 
were obtained from the Department of Physiologi- 
cal Chemistry, Karolinska Institutet. 3H-labelled 
5(6)-epoxy-C20: 3 (21 and 0.1 mCi/mmol) and 
14C-labelled 5(6)-epoxy-C20: 3 (56 mCi/mmol) 
were synthesized as in 19,111. Methyl-5-hydroxy~ 
PGII,, methyl-5-hydroxy-PGI,~, methyl-5(6)- 
epoxy-PGBi and methyl-5,6-dihydroxy-PGBi were 
synthesized as in [9,12]. 
2.2. Experimental 
Microsomes of RSV were resuspended in 0.1 M 
KH2PO4/K2~PO4 buffer (pH 8.0) with 1 mM 
sodium p-hydroxymercuribenzoate and 1 mM 
EDTA. In some experiments 1 mM phenol was 
added. Incubations were performed for 45 s in a 
water bath at 37°C by addition of the microsomal 
sus~nsion to an equal volume of buffer, which 
was kept at 37°C and contained the substrate. 3H- 
labelled 5(6)-epoxy-C20: 3 (15-20 x IO6 dpm) was 
incubated with microsomes from 0.5 g RSV in a 
total volume of 4 ml, while 1.5-2 mg epoxide 
(added in 30~1 ethanol) were incubated with 
microsomes from 6 g RSV in 44 ml. The two in- 
cubations were combined, acidified to pH 4 
(0.05 M E-ICI) and immediately extracted twice 
with cold diethyl ether. The ether extracts were 
kept on ice and dried over MgS04. After evapora- 
tion, the residue was dissoived in methanol 
(OS ml) and an ether solution of diazomethane 
(- 20°C) was immediatefy added in excess. After 
1 min the solvents were evaporated to dryness and 
the residue dissolved in dry acetone. 
2.3. Chramato~ra~~y 
The endoperoxides were dissolved in 30% 
diethyl ether in hexane and applied to an open col- 
umn of silicic acid (1 g), which was eluted with 
80 ml. The eluent was then changed to 50% 
(60 ml) and to 80% diethyl ether (60 ml) in hexane. 
Fractions of 5 ml were collected. The column was 
finally eluted with ethyl acetate. HPLC was per- 
formed as described in table 1. 
2.4. Chemical ~~~versian of enda~~raxides 
Reduction with SnClz in methanol (5 mg/ml) 
was performed as in [3]. The endoperoxides were 
also allowed to decay in 0.1 M K2HP04 buffer (pH 
7.4) with 1 mM EDTA for 30 min at 37°C [2,3]. 
2.5. Analyses 
The GC-MS analyses were performed on a 
quadrupole mass spectrometer (Finnigan 4000) 
equipped with a data acquisition system (Incas). 
An open capillary column of fused silica (20 m 
SE-54 CB) was operated isothermalIy at 270 or 
280°C. Splitless injections were performed with a 
‘falling needle’ device [ 131. The MS conditions 
were: electron energy, 70 eV; emission current, 
0.2 A; temperature of ion source, 300°C. C values 
were estimated from the retention times of 
saturated fatty acid methyl esters (CZO-C26). 
The UV analysis was performed with Zeiss 
Spektralphotometer PM 6 using ethanol as 
solvent. 
Table 1 
Elution volumes of prostaglandins on reversed-phase HPLC 
Compound Elution volume (ml) Compound Elution volume (ml) 
(55 :45 : 0.2) (65 :35 :0.2) 
5-HO-PGI,, 126 S-HO-PGIr, 35 
5-HO-PGIW 98 5-HO-PGI,p 30 
5(6)-Epoxy-l% S(6)-Epoxy-HHD 72 
hydroperoxy-PGEr 94 S(6)-Epoxy-PGBr 44 
S(6)-Epoxy-PGEr 78 
5,6-(HO)z-PGB, 81 
All compounds were chromatographed as methyl ester derivatives on IO ym octadecasilane siiica (7.8 x 300 mm, 
Nucleosil). The eluent was methanol-water-acetic acid as indicated (v/v). Flow rate was 1.5-2 ml/min and fractions 
were collected every minute 
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2.6. Derivatization 
Synthesis of Me$i and Me&-0-methoxime 
derivatives was performed as in [6,9,10]. 
Chlorohydrin adducts of epoxides were obtained 
as in [lo]. 
3. RESULTS 
3.1. Conversion of 5(6)-epoxyprostaglandin 
endoperoxides to known prostaglandins 
Following incubation of 3H-labelled 5(6)-epoxy- 
C20:3 with microsomes of RSV and extractive 
isolation, 35-50070 of radioactivity was recovered. 
The methylated crude extract from one experiment 
was divided into two parts. One part was reduced 
with SnClz and the polar products were separated 
by reversed-phase HPLC as shown in fig. 1A. Two 
major peaks of radioactivity appeared, which had 
the same elution volume as authentic methyl-5- 
hydroxy-PGIi, and methyl-5-hydroxy-PGIlp 
(table 1). The products could be conclusively iden- 
tified as these compounds by GC-MS and by dif- 
ferences in C values (Me3Si derivative [9]). The 
other part was allowed to decompose in buffer and 
the polar products were separated by reversed- 
phase HPLC (fig.lB). The most polar peak of 
radioactivity (peak I) contained methyl-5(6)- 
epoxy-PGEi, which was identified by GC-MS of 
the chlorohydrin adduct (Me3Si-0-methoxime 
derivative; [lo]) and by conversion to methyl-5,6- 
dihydroxy-PGBi by treatment with 0.1 M KOH 
(UV absorbance maximum at 278 nm; mass spec- 
trum of the Me3Si derivative [lo]). Treatment of 
the material in peak11 (fig.lB) with base also 
resulted in formation of a compound with max- 
imal UV absorbance at 278 nm. Following reduc- 
tion with GSH [2] and methylation, a mass spec- 
trum of methyl-5,6-dihydroxy-PGBi was obtained. 
Finally, reduction of the material in peak II with 
SnClz converted it to a major product, which had 
the same elution volume as methyl-5(6)-epoxy- 
PGEi on reversed-phase HPLC (fig.lC) and the 
product was identified as this compound by 
GC-MS as described above. The material in peak 
II was thus identified as methyl-5(6)-epoxy-15- 
hydroperoxy-PGEi (cf. [3]). 
3.2. Separation of methyl-5(6)-epoxy-PGG, and 
methyl-5(6)-epoxy-PGHI on silicic acid 
Addition of i4C-labelled 5(6)-epoxy-C20 : 3 at 
ELUTION VOLUME 
Fig. 1. Reversed-phase HPLC of polar products derived 
from methyl-5(6)-epoxy-PGGi and methyl-5(6)-epoxy- 
PGHi. (A) Endoperoxides were reduced by treatment 
with SnC12 in methanol. Peak I, methyl-5-hydroxy- 
PGIv; peak II, methyl-5-hydroxy-PGIi,. (B) Endoper- 
oxides were allowed to decompose in buffer. Peak I, 
methyl-5(6)-epoxy-PGEi; peak II, methyl-5(6)-epoxy- 
15-hydroperoxy-PGEi. (C) Part of the material in peak 
II of the chromatogram in B was reduced with SnC12 and 
rechromatographed as shown. The main product (peak 
I) was identified as methyl-5(6)-epoxy-PGEi. Column, 
1Opm octadecasilane silica (7.8 x 300 mm); eluent, 
methanol-water-acetic acid (55 : 45 : 0.2). Flow rate 
2 ml/min. 
the time of the extractive isolation showed that 
most of the substrate was eluted from the silicic 
acid column with the first l-2 fractions of 30% 
diethyl ether in hexane. On changing the eluent to 
50% ether, one major peak of radioactivity eluted 
and another peak eluted with 80% ether in hexane. 
The material in both peaks was converted to 
methyl-5-hydroxy-PGIi, and methyl-5-hydroxy- 
PGIw by reduction with SnC12. In buffer the first 
eluting compound decomposed mainly to methyl- 
5(6)-epoxy-15-hydroperoxy-PGEi as judged from 
reversed-phase HPLC, while the more polar com- 
pound was converted to methyl-5(6)-epoxy-PGEi 
(cf. fig.3). 
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3.3. Identification of methyl-5(6)-epoxy-HHD 
In buffer or by reduction with SnCll, the en- 
doperoxides were also converted to a product, 
which was less polar than the prostaglandins on 
reversed-phase HPLC (table 1). This compound 
was identified as methyl-S(6)-epoxy-HHD as 
follows: the UV analysis showed an absorbance 
maximum at 23 1 nm indicating the presence of two 
conjugated Pans double bonds [ 131. A mass spec- 
trum is shown in fig.2A (MeJSi derivative). Strong 
signals were noted at m/z 382 (M+), 364 (M+ - 18, 
loss of water), 311 (M+ - 71), 293 (M+ -99, 
possibly loss of water from m/z 31 l), 292 
(M+-90), 281 (cf. inset, fig.2A), 263 (possibly 
A 
100 
I I 
i 
111 
i :I 167 r x,5 L. 1?9 ^_. iSIMej 1 
M/7 
Fig.2. (A) Mass spectrum of methyl-5(6)-epoxy-HHD 
(MesSi derivative). (B) Mass spectrum of one of the 
chlorohydrin adducts of methyl-5(6)-epoxy-HHD, 
methyl-5-chloro-6-hydroxy-trans-8,1 l-heptadecadieno- 
ate (MesSi derivative). The natural abundance of “Cl 
(77%) and 37C1 (23%) gives a characteristic appearance 
of fragments containing chlorine. The insets show 
important fragments of the mass spectra, which were 
normalized to the most abundant signal above m/z 100. 
381- 18), 251, 225, 199, 181, 167, 143 (inset), 129 
and 111. The base peak was m/z 73 and the C 
value was 21.1. The GC-MS analysis of the 
chlorohydrin adducts (Me$Si derivative) showed 
that two major products were formed. The mass 
spectrum of the 5-chlorod-hydroxy adduct (C 
value 22.7) is shown in fig.2B. Signals were noted 
at m/z 490 (M+), 475 (M+ - 15), 459 (M+ - 31), 
419 (M+-71), 383, 365 (M+- 125, loss of 
MexSiOH and Cl), 341 (cf. inset), 292, 251 (cf. in- 
set), 219 (251 -32, loss of methanol), 191, 161, 
143, 119, 105 and 73 (base peak). The 
5-hydroxy-dchloro adduct (C value 22.9) also 
showed signals at m/z 490, 475, 459, 419, 383 and 
365. Other strong signals were noted at m/z 353, 
242, 225, 203 (cleavage between C5 and C6), 191, 
173, 171, 143, 129 and 73 (base peak). The UV and 
GC-MS analyses were consistent with the pro- 
posed structure. 
4. DISCUSSION 
Recent reports on the potent effects of 5(6)- 
epoxy-C20: 3 on the release of hormones from 
isolated pancreatic islets, the median eminence and 
rat pituitary cells [ 14- 161 stimulated interest in the 
J 
I16KPWPBE, 5,6~POYI-15-H”OROPEROX”-~E, 
Fig.3. Summary of the chemical conversion of 5(6)- 
epoxy-PGGi and 5(6)-epoxy-PGHi to prostaglandins. 
The compound within brackets, 5(6)-epoxy-PGFi,, has 
not been isolated, but 5-hydroxy-PGIi, and 5-hydroxy- 
PGIv are likely to be formed from this intermediate by 
intramolecular hydrolysis of the 5(6)-epoxide by the 
hydroxyl at C9 (9). Ri = (CH&COOCH3; R2 = 
(CHzkCH3. 
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possible metabolism of this epoxide to biologically 
active products. This report shows that 5(6)-epoxy- 
C20: 3 is metabolized by fatty acid cyclooxygenase 
to two prostaglandin endoperoxides, 5(6)-epoxy- 
PGGi and S(6)-epoxy-PGHi . The endoperoxides 
were characterized by their chemical conversion in- 
to known products as summarized in fig.3. The en- 
doperoxides were also partly transformed into 
S(6)-epoxy-HHD. 
Phenol stimulates the peroxidase activity of the 
prostaglandin synthesizing enzymes [ 171. In the 
presence of this cofactor 5(6)-epoxy-PGHr was ob- 
tained as the main product. This is in agreement 
with [18] and addition of phenol may be advan- 
tageous since PGG compounds are less stable than 
PGH compounds. PGG compounds can thus be 
non-enzymatically transformed into the correspon- 
ding 15keto derivatives [ 181. 
It will be of interest to determine whether 5(6)- 
epoxyprostaglandin endoperoxides are formed in 
vivo and to determine their biological effect. 
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